The latest price target for Lucid Diagnostics (NASDAQ:LUCD) was reported by Cantor Fitzgerald on November 15, 2024. The analyst firm set a price target for $2.00 expecting LUCD to rise to within 12 months (a possible 92.31% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Lucid Diagnostics (NASDAQ:LUCD) was provided by Cantor Fitzgerald, and Lucid Diagnostics maintained their overweight rating.

There is no last upgrade for Lucid Diagnostics

There is no last downgrade for Lucid Diagnostics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a maintained with a price target of $3.00 to $2.00. The current price Lucid Diagnostics (LUCD) is trading at is $1.04, which is out of the analyst’s predicted range.